Therapeutic anti-VEGF antibodies

Area of Science:

• Oncology
• Ophthalmology
• Immunology

Background:

• Vascular endothelial growth factor (VEGF-A) is crucial for blood vessel development in normal physiology and pathological conditions like cancer and wet age-related macular degeneration (AMD).
• Aberrant angiogenesis, driven by VEGF-A, contributes to tumor growth and vision loss in AMD.
• Targeting VEGF-A has emerged as a significant therapeutic strategy for various diseases.

Purpose of the Study:

• To review the molecular engineering of two humanized anti-VEGF antibodies: bevacizumab and ranibizumab.
• To discuss their therapeutic applications in oncology and ophthalmology.
• To highlight their efficacy in blocking VEGF-induced angiogenesis.

Main Methods:

• Review of scientific literature and clinical trial data.
• Analysis of the molecular engineering of bevacizumab (full-length IgG1) and ranibizumab (affinity-matured Fab domain).
• Examination of FDA-approved indications and therapeutic utility.

Main Results:

• Bevacizumab and ranibizumab are humanized antibodies derived from a common anti-VEGF mouse antibody.
• Bevacizumab is approved for specific cancer indications, while ranibizumab is approved for AMD.
• Both antibodies have demonstrated significant therapeutic utility in blocking VEGF-induced angiogenesis in clinical settings.

Conclusions:

• Molecular engineering has yielded effective anti-VEGF antibodies for therapeutic use.
• Bevacizumab and ranibizumab represent successful examples of targeted anti-angiogenic therapies.
• These antibodies offer valuable treatment options for cancer and AMD by inhibiting pathological angiogenesis.